2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Profiling, Treatment Considerations, Biological Therapies, Transplantation, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, Study Population, Human, Adult
PAPER

1724 Clonal dynamics and CSS, a clinical seven-feature risk score, predict relapse in single-cell MRD analysis of AML patients.

Enise Ceran, MD, Anne Merbach2, Saurabh Parikh3, Adam Sciambi, PhD4, Christian Rohde5, Fabian Fabian Beier, MD6, Robert Durruthy-Durruthy7, Zivjena Vucetic, MD, PhD8, Sonia Jaramillo-Segura, MD9, Richard F Schlenk, MD10, Christoph Röllig, MD11, Lutz Mueller12, Christian Junghanss, MD13, Claudia D Baldus, MD14, Uwe Platzbecker, MD15, Hubert Serve, MD16, Tim H. H. Brummendorf, MD17, Martin Bornhaeuser, MD18, Carsten Mueller-Tidow, MD19
1 Clinical Trial Center, National Center for Tumor Diseases Heidelberg, Heidelberg, Germany, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
2 Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
3 Mission Bio, South San Francisco, California, United States
4 Mission Bio, South San Francisco, California, United States
5 Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
6 Medical Faculty, RWTH Aachen University, Aachen, Germany
7 Mission Bio, South San Francisco, California, United States
8 Mission Bio, South San Francisco, California, United States
9 Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
10 Clinical Trial Center, National Center for Tumor Diseases Heidelberg, Heidelberg, Germany, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
11 National Center of Tumor Diseases Dresden, Dresden, Germany, University Hospital Carl Gustav Carus TU Dresden, Dresden, Germany
12 Martin Luther University Halle-Wittenberg, Halle (Saale), Germany
13 University Medicine Rostock, Rostock, Germany
14 University Medical Center Schleswig-Holstein, Kiel, Germany
15 University Hospital Leipzig, Leipzig, Germany
16 University Hospital Frankfurt, Goethe University, Frankfurt, Germany
17 Medical Faculty, RWTH Aachen University, Aachen, Germany
18 National Center of Tumor Diseases Dresden, Dresden, Germany, University Hospital Carl Gustav Carus TU Dresden, Dresden, Germany
19 Clinical Trial Center, National Center for Tumor Diseases Heidelberg, Heidelberg, Germany, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany

Background: In acute myeloid leukemia (AML), post-remission measurable residual disease (MRD) is a strong indicator of relapse and may aid in post-remission therapy decisions. Current genetics based MRD assays report a bulk quantity and do not resolve the clonal architecture or phenotypic state of residual cells, which eventually drive relapse. It remains unknown whether the clonal structure of residual disease carries prognostic information beyond clone count alone. Single-cell multiomic profiling addresses this by coupling genotype to immunophenotype at the clone level. This approach may identify relapse-driving subclones that would remain undetected by bulk approaches. If such architectural information proves predictive, it may help refine the allogeneic stem cell transplantation decision in first complete remission (CR1), a decision that weighs relapse risk against transplant-related mortality.

Methods:  Bone marrow samples from 43 AML patients in CR1 enrolled in the BLAST trial (NCT02502968) were analyzed using Tapestri-based single-cell multi-omics for scMRD, combining targeted DNA sequencing with surface protein profiling of a 40-gene myeloid panel and 19 markers. Clones were defined by co-occurring pathogenic variants and leukemic clones were distinguished from clonal hematopoiesis. We constructed a composite risk score integrating clone number with a clone-level seven-marker immunophenotypic signature (CD14, CD34, CD7, CD45RA, CD2, CD3, HLA-DR). Marker directions were pre-defined from AML biology, and the marker panel was derived on the cohort. Internal validation used leave-one-out cross-validation (LOOCV) and bootstrap resampling (1000 iterations). For 10 paired CR1-relapse samples we reconstructed clonal evolution using phylogenetic trees. Telomere length (T/S ratio) was assessed by PCR in 33 patients.

Results: The composite seven score (CSS) showed higher discrimination for relapse compared to clone number alone (AUC 0.75 vs 0.66; clone number log-rank p = 0.100). CSS stratified relapse-free survival (log-rank p = 9.7x10-4; HR = 4.32, 95% CI 1.68-11.14; 22 high-risk, 21 low-risk). At the optimized threshold, sensitivity was 0.74, specificity 0.75, PPV 0.77, NPV 0.71. LOOCV confirmed similar results. Bootstrap resampling gave a 90% AUC interval of 0.63-0.87.  Analyses of ten paired CR1-relapse samples detected relapse-driving clones as minor subclones at CR1 (e.g., NPM1/SMC1A from 0.3% to 2.8%). Telomere length did not predict relapse (AUC 0.46, p = 0.731) in this subcohort.

Conclusions: In this exploratory cohort, we introduce CSS, a composite seven feature single-cell score that integrates clonal architecture with the immunophenotype. CSS closely associated with relapse risk in AML at CR1. Internal validation retained the discriminative performance. If confirmed, single-cell MRD architecture may help refine post-remission risk stratification, particularly for the allogeneic transplantation decision in CR1. These findings require prospective validation in independent cohorts.

Enise Ceran, MD: No relevant conflicts of interest to declare.